REG - BiVictriX Therapcts. - Appointment of Adrian Howd as CFO and CBO

Bivictrix TherapeuticsAnnouncement

03/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231003:nRSC4416Oa&default-theme=true

RNS Number : 4416O  BiVictriX Therapeutics PLC  03 October 2023

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

 

 

Appointment of Adrian Howd as Chief Financial Officer

and Chief Business Officer

 

Alderley Park, 03 October 2023 - BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a differentiated approach to develop
novel, next-generation anti-cancer precision Antibody Drug Conjugates,
offering substantially improved cancer cell selectivity and therapeutic
activity, today announces that it has appointed Adrian Howd, PhD as combined
Chief Financial Officer ("CFO") and Chief Business Officer ("CBO"). Alex
Hughes will be stepping down from his position as CFO on 13 October.

 

Adrian joins BiVictriX with over 20 years of strategic financial and
commercial experience in the biopharmaceutical industry, having held various
financial roles, private and public executive management positions and board
roles across the sector. During his career to date he has led multiple asset
and corporate business development transactions, as well as numerous equity
capital market fundraises totalling over €430 million. Adrian possesses
substantial equity capital markets experience in the UK and overseas, gained
during his previous senior roles at Berenberg Bank, ABN Amro and Nomura.

 

Adrian has also held various senior management roles, including Chief
Investment Officer and Chief Executive Officer at investment firm, Malin plc,
where he led the Company to its debut on the Irish Stock Exchange in one of
the largest European life science initial public offerings to date.

 

At Malin, Adrian led investments in and served on the boards of both
Immunocore and Kymab, two "platform to therapeutic" UK-based companies, both
of which achieved multibillion USD exits via a NASDAQ IPO and a trade sale to
Sanofi respectively.

 

Tiffany Thorn, Chief Executive Officer of BiVictriX Therapeutics plc, added:
"We are delighted to welcome Adrian as Chief Financial Officer and Chief
Business Officer. His substantial financial acumen, combined with his strong
track record of strategic and operational success with UK oncology businesses
will be invaluable, as we look to secure partnership deals and accelerate
BiVictriX towards our next phase of development. On behalf of the entire team,
I would like to express my thanks to Alex for his contributions to the Company
and wish him all the best in his future endeavours."

 

Adrian Howd, newly appointed Chief Financial Officer and Chief Business
Officer of BiVictriX Therapeutics plc, said: "BiVictriX Therapeutics has
reached a critical inflection point, having achieved compelling and
differentiated pre-clinical data for its lead asset as well as broadening the
technology pipeline and building the foundations of a robust, patent-protected
portfolio. I strongly believe in the potential of the Bi-Cygni® Platform to
revolutionise cancer therapy and the Company has multiple strategic options,
for its lead asset and also in the wider solid tumour space. At this point in
the Company's evolution, I see parallels between other companies I have
successfully worked with in the oncology space and I am looking forward to
joining Tiffany and the wider BiVictriX team to maximise shareholder value
from the science."

 

 ENDS

 For more information, please contact:

BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer

 Michael Kauffman, Non-Executive Chairman             Email: info@bivictrix.com (mailto:info@bivictrix.com)

 SP Angel Corporate Finance LLP (NOMAD and Broker)      Tel: +44 (0) 20 3470 0470
 David Hignell, Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon (UK) Limited (Joint Broker)             Tel: +44 (0) 20 7886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 ICR Consilium
 Mary-Jane Elliott, Namrata Taak,                     Tel: +44 (0) 20 3709 5700

 Max Bennett, Emmalee Hoppe                           Email: Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a new class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst significantly reducing treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed
to selectively target cancer-specific antigen pairs, or "Bi-Cygni®
fingerprints", on tumour cells, which are largely absent from healthy cells.

 

BiVictriX has established a growing proprietary library of cancer-specific
Bi-Cygni® fingerprints, which enable the Company to target a diverse array of
different cancer types. The Company utilises these novel Bi-Cygni®
fingerprints, together with the Company's novel Antibody Drug Conjugate
therapeutic design, to develop more effective and safer therapeutics to target
cancers that are expected to constitute orphan indications and areas of high
unmet medical need.

 

Find out more about BiVictriX online at www.bivictrix.com
(http://www.bivictrix.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUUOBROWURRAA